A Multicenter Phase II Open Study Coupled With a Translational Assessment of Biomarkers Predictive of Response to Sunitinib in Patients With Poorly-differentiated Advanced/Inoperable NEURO-Endocrine Tumors.
Phase of Trial: Phase II
Latest Information Update: 23 Jan 2016
At a glance
- Drugs Sunitinib (Primary)
- Indications Neuroendocrine tumours
- Focus Biomarker; Therapeutic Use
- 13 Aug 2013 Planned end date changed from 1 Apr 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 12 Oct 2010 New trial record